IRCT20220211053992N16RecruitingUnknown
In vivo bioequivalence study of Omeprazole 20 mg capsule of Temad pharmaceutical Co. compared to innovator product
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 59 years (—)
- Sex
- All
Inclusion Criteria
- •General Health (in terms of Liver, Heart and Kidney)
- •Age (18-59 years old)
Exclusion Criteria
- •History of cardiovascular, liver and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
Investigators
Similar Trials
Completed
Not Applicable
Bioequivalance study of Omeprazole 20mgIRCT20200513047423N2Sina Pishgam Darou Novin24
Recruiting
Not Applicable
Study of absorption and elimination rate of omeprazole 20 mg capsule in comparison with omeprazole brand capsules (Prilosec®).bioequivalence study.IRCT20200407046981N19Yas Kavir Meybod Pharmaceutical Company24
Not yet recruiting
Not Applicable
Study of absorption and elimination rate of omeprazole 10-mg Sachet in comparison with omeprazole brand Sachet (Nexium®).IRCT20200407046981N20Kimia Kala Razi Pharmaceutical Company24
Completed
Not Applicable
Comparative bioequivalence study of the Omeprazole 10-mg Sachet manufactured by Nafas Zist Pharmed Pharmaceutical CompanyIRCT20130313012810N9afas Zist Pharmed Pharmaceutical Company24
Not yet recruiting
Not Applicable
Bioequivalence study of manufactured by Esmoprazole 40mg Cap. Kooshan Pharmed. Co. (Eosoflux) in Iranian healthy volunteersIRCT20200105046010N7Tabriz University of Medical Sciences24